Streetbeat News

Products Services

IRON

Disc Medicine has been granted FDA Fast Track Designation for its drug DISC-0974, aimed at treating anemia in patients with non-dialysis dependent chronic kidney disease. This designation could expedite the drug's development and review process, potentially bringing it to market sooner.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:31 pm

ALGS

Aligos Therapeutics, Inc. (NASDAQ:ALGS) announced a virtual KOL event on March 7, 2024, to discuss the Phase 2a HERALD study of ALG-055009 in MASH, featuring Stephen Harrison, MD. The event will cover the unmet need and current treatment landscape for MASH and the safety and efficacy of ALG-055009, a next-generation thyroid hormone beta agonist.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:31 pm

AMTX

Aemetis, Inc. (NASDAQ:AMTX) announced its updated Five Year Plan, projecting significant growth with $1.95 billion in revenues and $645 million in adjusted EBITDA by 2028. The plan highlights a compound annual growth rate of 38% in revenues and 83% in adjusted EBITDA from 2024 to 2028, driven by expansions in renewable natural gas, sustainable aviation fuel, renewable diesel, and biodiesel production, as well as carbon sequestration projects. The company also noted financial support from the USDA and benefits from the Inflation Reduction Act.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:30 pm

JANX

Janux Therapeutics, Inc. (NASDAQ:JANX) announced a virtual event on February 26th, 2024, to discuss updated clinical data for its immunotherapies JANX007 and JANX008. JANX007 targets PSMA for prostate cancer and is in Phase 1 trials. JANX008 targets EGFR for various cancers including lung and colorectal, also in Phase 1 trials. The event will include efficacy and safety updates, with a focus on dose identification for expansion studies.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:27 pm

STLA

Stellantis NV announced that starting in 2024, DS Automobiles will standardize the inclusion of ChatGPT in models equipped with the DS Iris System, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:25 pm

SKIL

Skillsoft (NYSE:SKIL) announced enhancements to its Codecademy platform, integrating generative AI (GenAI) to provide immersive technology skills training. The updates include AI-powered capabilities like prompt engineering functionality, code explanations, project hints, a mock interview simulator, and a virtual coding assistant. These enhancements aim to help learners and organizations build critical technology skills for the AI era. Skillsoft also plans to expand its curricula to include more AI skills training, with new courses on prompt engineering for various professions.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:24 pm

ALK

Alaska Airlines has introduced an exclusively brewed beer, presented in a unique can, as part of its premium beverage offerings. This move aims to enhance the in-flight experience for passengers, potentially attracting more customers who value unique and premium beverage options during their flights.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:24 pm

CNHI

CNH Industrial (CNHI) has taken a minority investment in Bem Agro, a Brazilian AI company specializing in drone imaging for agriculture. This investment aims to enhance CNH's Ag Tech solutions, making farming more efficient and sustainable. Bem Agro's technology, which has been in commercial partnership with CNH for over five years, provides Agronomic Mapping Reports from aerial images to optimize farming operations. The technology is already integrated into CNH's Case IH and New Holland brands in Brazil, Indonesia, and Thailand, aiming to expand its precision technology solutions across Latin America and Asia Pacific.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:20 pm

PRPH

ProPhase Labs, Inc. (NASDAQ:PRPH) announced progress in the development of its BE-SMART esophageal cancer diagnostic test, including the grant of broad patents by the USPTO and positive preliminary results from additional specimen analyses. The test, aimed at detecting early signs of cancer in individuals with Barrett's esophagus, is nearing the end of its clinical studies, with a commercial launch targeted for 2024. The test has shown over 99% molecular precision and has been tested on over 200 human samples. ProPhase Labs plans to commercialize BE-SMART as a laboratory-developed test (LDT), with potential wide-scale adoption targeting over 20 million Americans monitored for Barrett's esophagus.

Portfolio Pulse from Happy Mohamed

February 20, 2024 | 1:19 pm

NVO

WMT

The popularity of weight-loss drugs like Ozempic is prompting investors to push food companies towards healthier offerings, as a Bloomberg survey shows 75% of respondents advocating for business model adjustments. This trend is seen as a threat to traditional food companies, with Walmart Inc. noting a decrease in calorie purchases. Industry experts and CEOs are concerned about the impact of these drugs on food and beverage sales.

Portfolio Pulse from Benzinga Neuro

February 20, 2024 | 1:18 pm